Answers are grounded in this paper and cite their sources.
Nowadays HIV-infected patients seem sentenced to a lifelong struggle against a lot of enemies. They can be jeopardized by AIDS-related morbimortality, treatment side effects, heavy pill burdens (fortunately this is gradually improving) and, something too frequently ignored, social stigma. Only people in close contact with patients become really aware of the suffering involved in their attempts to keep their HIV condition hidden from sons, parents, friends, workmates or employers. HIV infection is a heavy load on social and professional life, loneliness and unemployment are common companions. Wasting syndrome and Kaposi's sarcoma, the classic stigmatizing lesions, are now less frequent; however a new enemy of privacy has appeared: lipoatrophy, in particular facial lipoatrophy. Lipodystrophy syndrome is a major problem for the long-term use of highly active antiretroviral therapy (HAART), however peripheral fat wasting as a consequence of drug therapy in patients with normal daily caloric and nutrient intake has never been reported before in the history of medicine. Hence, it is not surprising that the pathogenesis of HIV-associated lipoatrophy, probably a multifactorial phenomenon, is still poorly understood [1,2]. A broad array of risk factors for lipoatrophy has been reported, some related to treatment (use and duration of antiretrovirals, both retrotranscriptase and protease inhibitors) [3], others related to HIV-infection (CD4 cell counts, viral load, history of AIDS) [4] and another group related to host (age, sex, race, genetics) [5]. Even a simple, precise definition of a case of ‘HIV-associated lipoatrophy’ is still lacking [6]. So initial, subtle changes can only be diagnosed subjectively. Lipoatrophy affects all groups of treated patients, even those treated very soon after the primary HIV infection [7]; lipoatrophy in the naive patient remains anecdotal. Amongst all the affected patients we are especially indebted to those who began treatment in a setting that today would not be recommended. By this, I mean the patients of the ‘hit hard hit early’ times who began HAART when their CD4 cell counts were well over 350 × 106/l or even 500 × 106/l. For many of those patients severe facial lipoatrophy has been a high price to pay for a very small gain. Current strategies to reverse lipoatrophy have offered poor results. Pharmacologic approaches (rosiglitazone, pioglitazone, metformine, growth hormone) have not obtained encouraging enough results to justify their use [8–11]. HAART changes to potentially less atrophiant regimens offer, at best, very modest improvements [12–14]. Even treatment suspension has failed to induce a noticeable fat atrophy recovery [15]. In this scenario it cannot be surprising that lipoatrophy is now reaching the top of the list of causes of poor adherence to antiretroviral treatment [16]. With the current limited knowledge of the causes and pathogenic mechanisms of lipoatrophy, a definitive solution cannot be reasonably expected in the short term, unless serendipity helps us. In the last few years many informed, anxious and desperate patients, well aware of the limitations of lipoatrophy treament, have looked for help in surgical approaches. Preliminary results of surgical treatment of facial atrophy using autologous fatty tissue [17], submalar silicone implants [18] or injections of hyaluronic acid [19] or of several synthetic polymers have been recently communicated [20–22]. A small number of patients, short follow-up or the need of general anaesthesia have been common drawbacks of these studies. In this issue Valantin et al. [23] report the results of a series of 50 patients with severe lipoatrophy treated with facial injections of polylactic acid (New-Fill) and followed up for 72 weeks. Polylactic acid is a biocompatible and immunologically inert synthetic polymer which belongs to the class of resorbable biomaterials. This product has been safely used in a variety of orthopedic and maxillofacial applications since the mid-1990s and was approved in Europe in 1999 for the cosmetic correction of scars and wrinkles. Valantin's patients received between three and five sets of injections at day 0 and then every 2 weeks, according to clinical results. In each session patients were injected a mean of 4 ml of substance. At the end of follow-up aesthetic and quality of life improvements seem excellent. Not only is it effective, but the procedure is simple, ambulatory and does not need general anaesthesia, all making it particularly attractive. If these results are confirmed by other groups, probably dermatologists and plastic surgeons will not find it too troublesome to implement this technique in their units. Results seem relatively long lasting and the cost affordable (in Spain the price of New-Fill is about 65 €/ml). Concern remains about the durability of the procedure beyond 72 weeks, for 18 months is the average duration of the benefits of polylactic acid injections in other indications such as scars or wrinkles. In the study by Valantin et al. all of the injections were given by ‘the same trained dermatologist'. This means that, only with the patients included in this paper, he/she administered more than 400 injections, a real expert. I wonder if the excellent results and the minimum incidence of serious adverse effects obtained in this study would also be achieved by less experienced hands. Before this technique arrives in the usual clinical practice the necessary training to perform these procedures safely has to be clearly defined and these results must be reproduced by other groups. A word of caution is also needed against the clandestine use of New-Fill by unlicenced people. This has been a common problem with other injectable cosmetic products particularly among the marginal population. But the fight against lipoatrophy has to go on. The difficulties in reversing the lipoatrophy and unravelling its mechanisms will probably lead to a three-step way until final resolution. First, a refinement of the knowledge of associated factors will permit to design preventive strategies (to define the best time along the natural history of HIV infection to begin HAART in order not to induce lipoatrophy, for example). In a second step, a more comprehensive knowledge of the causes of lipoatrophy will probably allow us to choose the antiretroviral regimes with the lowest risk of inducing lipoatrophy. The third step will be a complete understanding of the lipoatrophy phenomenon and the engineering of antiretroviral drugs devoid of the power of inducing lipoatrophy and specific drugs able to reverse the atrophy. Unfortunately, to reach this final stage will take years. In the meantime, the results of Valantin et al. are good news. At last we have something with clear results to offer our patients. HIV-patients stigmatization is not a medical problem but a social one. With facial atrophy treatment we will not change social rejection overnight but, undoubtedly we will help our patients in their daily efforts and, even more, we will help them to keep self-esteem and quality of life. HIV-infected patients with lipoatrophy can now have a new smile on their face. Arms, legs and buttocks go on waiting. Acknowledgements The author acknowledges the assistance and advice of J. Portilla (Unit of Infectious Diseases, Hospital General Universitario de Alicante, Spain).
No takes yet. Share an insight, caveat, or question.
Vicente Boix (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: